HomeCompareBDSI vs MAIN

BDSI vs MAIN: Dividend Comparison 2026

BDSI yields 35.78% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.76M in total portfolio value· pulled ahead in Year 5
10 years
BDSI
BDSI
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full BDSI calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — BDSI vs MAIN

📍 MAIN pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDSIMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDSI + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDSI pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDSI
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,153,362.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDSI + MAIN for your $10,000?

BDSI: 50%MAIN: 50%
100% MAIN50/50100% BDSI
Portfolio after 10yr
$24.07M
Annual income
$20,118,485.74/yr
Blended yield
83.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDSI right now

BDSI
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDSI buys
0
MAIN buys
0
No recent congressional trades found for BDSI or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDSIMAIN
Forward yield35.78%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$183.7K$47.95M
Annual income after 10y$28,272.37$40,208,699.11
Total dividends collected$133.5K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold

Year-by-year: BDSI vs MAIN ($10,000, DRIP)

YearBDSI PortfolioBDSI Income/yrMAIN PortfolioMAIN Income/yrGap
1$14,278$3,577.82$12,464$1,223.78+$1.8KBDSI
2$20,051$4,774.15$16,353$2,343.58+$3.7KBDSI
3$27,721$6,266.08$23,105$4,724.42+$4.6KBDSI
4$37,758$8,096.12$36,226$10,256.23+$1.5KBDSI
5← crossover$50,707$10,305.96$65,426$24,707.64$14.7KMAIN
6$67,191$12,934.95$142,101$68,562.02$74.9KMAIN
7$87,913$16,018.70$388,521$228,799.95$300.6KMAIN
8$113,655$19,587.81$1,397,868$961,169.80$1.28MMAIN
9$145,277$23,666.62$6,884,663$5,313,459.69$6.74MMAIN
10$183,719$28,272.37$47,947,060$40,208,699.11$47.76MMAIN

BDSI vs MAIN: Complete Analysis 2026

BDSIStock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Full BDSI Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this BDSI vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDSI vs SCHDBDSI vs JEPIBDSI vs OBDSI vs KOBDSI vs ARCCBDSI vs HTGCBDSI vs GBDCBDSI vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.